Last reviewed · How we verify
AB103
AB103 is a monoclonal antibody targeting the PD-1 receptor.
AB103 is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.
At a glance
| Generic name | AB103 |
|---|---|
| Also known as | p2TA |
| Sponsor | Atox Bio Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, AB103 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Hypertension
Key clinical trials
- Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury (PHASE3)
- Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections (PHASE3)
- Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients (PHASE2)
- AB103 Peptide Antagonist in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB103 CI brief — competitive landscape report
- AB103 updates RSS · CI watch RSS
- Atox Bio Ltd portfolio CI